WO1997015331A1 - Methods of preserving microorganisms - Google Patents

Methods of preserving microorganisms Download PDF

Info

Publication number
WO1997015331A1
WO1997015331A1 PCT/GB1996/002615 GB9602615W WO9715331A1 WO 1997015331 A1 WO1997015331 A1 WO 1997015331A1 GB 9602615 W GB9602615 W GB 9602615W WO 9715331 A1 WO9715331 A1 WO 9715331A1
Authority
WO
WIPO (PCT)
Prior art keywords
micro
amphiphile
organisms
virus particles
polyoxyethylene
Prior art date
Application number
PCT/GB1996/002615
Other languages
French (fr)
Inventor
Roger Randal Charles New
Charles Anthony Hart
Original Assignee
Cortecs (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs (Uk) Limited filed Critical Cortecs (Uk) Limited
Priority to KR1019980702966A priority Critical patent/KR19990067029A/en
Priority to NZ320446A priority patent/NZ320446A/en
Priority to EP96935088A priority patent/EP0857069A1/en
Priority to BR9610932-7A priority patent/BR9610932A/en
Priority to JP9516410A priority patent/JP2000501282A/en
Priority to AU73183/96A priority patent/AU714485B2/en
Publication of WO1997015331A1 publication Critical patent/WO1997015331A1/en
Priority to US09/065,734 priority patent/US6165773A/en
Priority to NO981865A priority patent/NO981865L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to methods of preserving micro-organisms such that they retain their infectivity.
  • the invention relates to methods of preserving viral particles.
  • Vaccines comprising viral particles have been in use for a number of years. It is, however, essential that such vaccines can be stored, sometimes for long periods, without the viral component losing its infectivity.
  • Common storage methods include freezing or freeze-drying, the latter usually involving reconstitution using water at a later stage.
  • certain viruses display reduced viability/infectivity when subjected to these processes .
  • One virus which is not suitably stored as described above is polio virus. This virus is readily degraded at room temperature in aqueous suspension, is stable for only two weeks at 0°C and is destroyed by lyophilisation.
  • preferred methods of storage involve freezing at -70°C or refridgeration at 4°C.
  • such storage conditions are not particularly suitable for use in tropical countries or indeed countries where the required facilities and equipment are scarce.
  • compositions comprising a hydrophilic species solubilised in a hydrophobic phase, as well as methods for their preparation.
  • UK application no. 9424901.8 discloses compositions as - described in PCT/GB94/02495 which incorporate additional components which aid retention of the hydrophilic species in the hydrophobic phase.
  • UK application no.9424902.6 discloses compositions as described in PCT/GB94/02495 which incorporate moieties which aid formation of the composition.
  • UK patent application no. 9422990.3 discloses immunogenic compositions which comprise an immunogen solubilised, suspended or otherwise dispersed in a hydrophobic phase.
  • the immunogen can be a virus and the compositions are useful as vaccines .
  • micro-organisms particularly virus particles, such as polio virus particles
  • virus particles such as polio virus particles
  • polio virus particles may be converted to a form suitable for long term storage at ambient temperature, with retention of infectivity after reconstitution in aqueous medium.
  • such compositions have particular advantages for use in countries where the ususal storage methods are less appropriate, and provide an effective means by which such viruses can be transported and stored without the need for extreme freezing or prolonged refridgeration.
  • the present invention provides a method of storing micro-organisms such that they maintain infectivity, which method includes the steps of :-
  • micro-organisms are virus particles particularly polio virus particles.
  • Suitable methods for carrying out the above method are those described in PCT/GB94/02495, UK 9424901.8, UK 9424902.6 and UK 9422990.3.
  • the hydrophobic solvent could for example be a long chain fatty acid, a medium chain alcohol, a branched long chain alcohol, a monoglyceride, a diglyceride, a medium chain triglyceride, a long chain triglyceride, a halogenated (e.g. fluorinated) analogue thereof, or a polyoxyethylene-containing lipid.
  • the hydrophobic solvent is a mono-, di- or tri-glyceride, or oleic acid.
  • the method comprises : (i) co-dispersing the micro-organisms with an amphiphile in a liquid medium;
  • the liquid medium can be water, and it can be removed by, e.g. freeze drying, centrifugal vacuum drying or any other suitable method.
  • the amphiphile will be a phospholipid, for instance one with a phosphatidyl choline head group, eg phosphatidyl choline (PC) , lysophosphatidyl choline (lyso-PC) , sphingomyelin or a derivative of one of these such as hexadecyl phosphocholine or an amphiphile polymer containing phosphoryl choline.
  • a phosphatidyl choline head group eg phosphatidyl choline (PC) , lysophosphatidyl choline (lyso-PC) , sphingomyelin or a derivative of one of these such as hexadecyl phosphocholine or an amphiphile polymer containing phosphoryl choline.
  • a phosphatidyl choline head group eg phosphatidyl choline (PC) , lysophosphati
  • a bile salt a glycolipid, a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24 , polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
  • the micro ⁇ organisms eg virus particles
  • This array is then in turn coated with the hydrophobic solvent .
  • access to the micro-organisms by water is restricted, which in turn accounts for the improved storage properties when the micro-organism preparation is reconstituted from a freeze-dried state.
  • the present invention provides a method of storing micro-organisms such that they retain infectivity, which method includes the following steps:
  • the water is removed by freeze-drying.
  • the amphiphile can be a phospholipid, for instance one with a phosphatidyl choline head group, eg phosphatidyl choline (PC) , lysophosphatidyl choline (lyso-PC) , sphingomyelin or a derivative of one of these such as hexadecyl phosphocholine or an amphiphile polymer containing phosphoryl choline.
  • a phosphatidyl choline head group eg phosphatidyl choline (PC) , lysophosphatidyl choline (lyso-PC) , sphingomyelin or a derivative of one of these such as hexadecyl phosphocholine or an amphiphile polymer containing phosphoryl choline.
  • a phosphatidyl choline head group eg phosphatidyl choline (PC) , lysophosphati
  • a bile salt a glycolipid, a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24, polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
  • the amphiphile is Solulan C24, polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g Cremaphor EL35.
  • the amphiphile is Solulan C24 or polyoxyethylene 40 stearate.
  • the method also includes the step of elevating the temperature of the mixture after removal of the water. This ensures that the structure adopted by the amphiphile/micro-organism array . is more condensed, which in turn results in more restricted access for water upon reconstitution.
  • the amphiphile will be one which remains solid after the water removal step, eg it can be chosen from a phospholipid, for instance lecithin, a glycolipid, a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24 , polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
  • a phospholipid for instance lecithin
  • a glycolipid e.g., a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24 , polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative,
  • a micro-organism composition obtainable by any of the methods described herein, particularly a micro- organism composition comprising virus particles, eg polio virus particles; and
  • composition of the invention for the storage of virus particles.
  • Preferred features of each aspect of the invention are as for each other aspect mutatis mutandis .
  • a suspension of IO 9 polio virus particles (Sabin strains, Types 1, 2, 3) per ml of culture was diluted 1000-fold in distilled water. 1ml of the diluted suspension was mixed with 1ml of adispersion of sonicated soya phospholipid
  • control vial (at a concentration of lOOmg/ml) in distilled water.
  • a control vial was prepared which contained virus only, without the addition of phospholipid.
  • a control vial of polio virus was prepared as above. To this control vial, containing virus alone, was added lml of culture medium.
  • lO ⁇ l of oil/virus preparation was transferred to a fresh vial, and lml of a 2% solution of ox bile extract (containing predominantly sodium taurocholate) was added.
  • Example 2 A virus suspension (Sabin strains, Types 1, 2, 3) containing 5xlO e particles/ml (spun to remove contaminating protein) was diluted 50-fold by addition of 200 ⁇ l of the suspension to 9.9ml of distilled water, yielding a concentration of IO 7 particles/ml. The suspension was divided into four equal aliquots of 2.5ml, and dispensed into 7ml screw-capped glass vials. One aliquot was employed in the experiment described herein, while two were used in the experiment described in example 3.
  • sonicated phospholipid dispersion (lOOmg/ml) was added to the aliquot of diluted virus particles with gentle mixing. 200 ⁇ l of this mixture was dispensed into 20 freeze-drying vials, and the remainder was transferred, In lOO ⁇ l aliquots, into other tubes as "pre ⁇ drying" controls. The controls were stored overnight at +4°C. The freeze-drying vials were placed in the centrifugal rotor of the freeze-dryer and lyophilised overnight .
  • the suspensions prepared above were used to perform 10- fold dilutions in Vero cell monolayer cultures, in order to measure the viability of the polio virus present, the results were expressed as the highest dilution at which 50% cytopathic effects were observed. Nature of sample Highest dilution at which 50% cytopathic effects were observed. Nature of sample Highest dilution at which 50% cytopathic effects were observed. Nature of sample Highest dilution at which
  • the suspensions prepared as described herein were used to perform 10-fold dilutions in Vero cell cultures, to measure the viability of the polio virus present. The results were expressed as the highest dilution at which 50% cytopathic effects were observed.

Abstract

Methods for preserving microorganisms including viruses, such that infectivity is retained, are provided, as well as the use of such methods in preparing e.g. vaccines.

Description

METHODS OF PRESERVING MICROORGANISMS
The present invention relates to methods of preserving micro-organisms such that they retain their infectivity. In particular the invention relates to methods of preserving viral particles.
Storage/viability problems occur in relation to micro¬ organism storage. In particular problems occur in relation to viral storage where the virus particles are employed for uses such as: -
(a) viral vectors for use in, e.g. gene therapy;
(b) storage of viruses for general research progress, e.g. in culture banks;
(c) viruses to be used for release into the environment for control of agricultural pests; and
(d) vaccines.
Vaccines comprising viral particles have been in use for a number of years. It is, however, essential that such vaccines can be stored, sometimes for long periods, without the viral component losing its infectivity. Common storage methods include freezing or freeze-drying, the latter usually involving reconstitution using water at a later stage. Unfortunately, certain viruses display reduced viability/infectivity when subjected to these processes . One virus which is not suitably stored as described above is polio virus. This virus is readily degraded at room temperature in aqueous suspension, is stable for only two weeks at 0°C and is destroyed by lyophilisation. For this particular virus preferred methods of storage involve freezing at -70°C or refridgeration at 4°C. However, such storage conditions are not particularly suitable for use in tropical countries or indeed countries where the required facilities and equipment are scarce.
International Application No PCT/GB94/02495 discloses compositions comprising a hydrophilic species solubilised in a hydrophobic phase, as well as methods for their preparation. UK application no. 9424901.8 discloses compositions as - described in PCT/GB94/02495 which incorporate additional components which aid retention of the hydrophilic species in the hydrophobic phase. UK application no.9424902.6 discloses compositions as described in PCT/GB94/02495 which incorporate moieties which aid formation of the composition.
In addition, UK patent application no. 9422990.3 discloses immunogenic compositions which comprise an immunogen solubilised, suspended or otherwise dispersed in a hydrophobic phase. The immunogen can be a virus and the compositions are useful as vaccines .
It has now been found that micro-organisms, particularly virus particles, such as polio virus particles, may be converted to a form suitable for long term storage at ambient temperature, with retention of infectivity after reconstitution in aqueous medium. Thus, such compositions have particular advantages for use in countries where the ususal storage methods are less appropriate, and provide an effective means by which such viruses can be transported and stored without the need for extreme freezing or prolonged refridgeration.
Thus, in a first aspect, the present invention provides a method of storing micro-organisms such that they maintain infectivity, which method includes the steps of :-
(i) bringing the micro-organisms into association with an amphiphile; and
(ii) solubilising, suspending or otherwise dispersing the micro-organisms in a hydrophobic phase.
In one preferred embodiment the micro-organisms are virus particles particularly polio virus particles.
Suitable methods for carrying out the above method are those described in PCT/GB94/02495, UK 9424901.8, UK 9424902.6 and UK 9422990.3.
The hydrophobic solvent could for example be a long chain fatty acid, a medium chain alcohol, a branched long chain alcohol, a monoglyceride, a diglyceride, a medium chain triglyceride, a long chain triglyceride, a halogenated (e.g. fluorinated) analogue thereof, or a polyoxyethylene-containing lipid.
In particular embodiments the hydrophobic solvent is a mono-, di- or tri-glyceride, or oleic acid.
In one preferred embodiment the method comprises : (i) co-dispersing the micro-organisms with an amphiphile in a liquid medium;
(ii) removing the liquid medium to leave an array of amphiphile molecules with their hydrophilic head groups orientated towards the micro-organism; and
(iii) providing a non-aqueous solvent around the micro-organisms/amphiphile array.
The liquid medium can be water, and it can be removed by, e.g. freeze drying, centrifugal vacuum drying or any other suitable method.
Suitably, in the above methods the amphiphile will be a phospholipid, for instance one with a phosphatidyl choline head group, eg phosphatidyl choline (PC) , lysophosphatidyl choline (lyso-PC) , sphingomyelin or a derivative of one of these such as hexadecyl phosphocholine or an amphiphile polymer containing phosphoryl choline. A bile salt, a glycolipid, a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24 , polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
Without wishing to be bound by the following, it is believed that in the methods described above the micro¬ organisms, eg virus particles, first form an array with the amphiphile molecules. This array is then in turn coated with the hydrophobic solvent . In this way access to the micro-organisms by water is restricted, which in turn accounts for the improved storage properties when the micro-organism preparation is reconstituted from a freeze-dried state.
In a second aspect, the present invention provides a method of storing micro-organisms such that they retain infectivity, which method includes the following steps:
(i) bringing the micro-organisms into association with an amphiphile in an aqueous phase; and
(ii) removing the water.
Preferably, the water is removed by freeze-drying.
The amphiphile can be a phospholipid, for instance one with a phosphatidyl choline head group, eg phosphatidyl choline (PC) , lysophosphatidyl choline (lyso-PC) , sphingomyelin or a derivative of one of these such as hexadecyl phosphocholine or an amphiphile polymer containing phosphoryl choline. A bile salt, a glycolipid, a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24, polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
In a particularly preferred embodiment of this aspect the amphiphile is Solulan C24, polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g Cremaphor EL35. In particularly preferred embodiments the amphiphile is Solulan C24 or polyoxyethylene 40 stearate.
It is possible that upon removal of the water the amphile/micro-organism array will be in an "open" form. Thus, upon reconstitution water may still have access to the micro-organisms and this will lead to loss of infectivity. Therefore, in another preferred embodiment of this aspect of the invention the method also includes the step of elevating the temperature of the mixture after removal of the water. This ensures that the structure adopted by the amphiphile/micro-organism array. is more condensed, which in turn results in more restricted access for water upon reconstitution.
When the heating step is employed, the amphiphile will be one which remains solid after the water removal step, eg it can be chosen from a phospholipid, for instance lecithin, a glycolipid, a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24 , polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
In other aspects the invention provides
i) a micro-organism composition obtainable by any of the methods described herein, particularly a micro- organism composition comprising virus particles, eg polio virus particles; and
ii) the use of a composition of the invention for the storage of virus particles. Preferred features of each aspect of the invention are as for each other aspect mutatis mutandis .
The invention will now be described with reference to the following example, which should not be construed as in any way limiting the invention.
Example 1
A suspension of IO9 polio virus particles (Sabin strains, Types 1, 2, 3) per ml of culture was diluted 1000-fold in distilled water. 1ml of the diluted suspension was mixed with 1ml of adispersion of sonicated soya phospholipid
(at a concentration of lOOmg/ml) in distilled water. A control vial was prepared which contained virus only, without the addition of phospholipid.
The contents of both vials were shell-frozen in liquid nitrogen and lyophilised overnight. The following day, lml of oleic acid was added to the vial containing virus and phospholipid, and the contents of the vial wre then mixed on a roller mixer for several hours. A clear solution was obtained.
A control vial of polio virus was prepared as above. To this control vial, containing virus alone, was added lml of culture medium.
lOμl of oil/virus preparation was transferred to a fresh vial, and lml of a 2% solution of ox bile extract (containing predominantly sodium taurocholate) was added.
The mixture was shaken well to disperse the oil in water, with the intention of releasing particles into the aqueous phase. Ten-fold serial dilutions were made in culture medium, and 0.5ml of each dilution was added to confluent monolayers of Viro cells, and incubated for four days, to test for the presence of intact virus. An identical procedure was followed for the contents of the control vial. Growth was assessed by visual observation of virus-induced cell lysis in each monolayer. Growth was recorded in the two series of dilutions as follows:
Dilution of lyophilisate IO2 IO3 IO4 IO5 IO6 Virus particles present IO4 IO3 IO2 10 1 (per ml)
Oil-based lyophilisate + + + + Oil-free lyophilisate + + - - -
These results indicate that the method of the present invention clearly improves the viability of stored viral preparations, when compared to lyophilisation alone.
Example 2 A virus suspension (Sabin strains, Types 1, 2, 3) containing 5xlOe particles/ml (spun to remove contaminating protein) was diluted 50-fold by addition of 200μl of the suspension to 9.9ml of distilled water, yielding a concentration of IO7 particles/ml. The suspension was divided into four equal aliquots of 2.5ml, and dispensed into 7ml screw-capped glass vials. One aliquot was employed in the experiment described herein, while two were used in the experiment described in example 3.
2.5ml of sonicated phospholipid dispersion (lOOmg/ml) was added to the aliquot of diluted virus particles with gentle mixing. 200μl of this mixture was dispensed into 20 freeze-drying vials, and the remainder was transferred, In lOOμl aliquots, into other tubes as "pre¬ drying" controls. The controls were stored overnight at +4°C. The freeze-drying vials were placed in the centrifugal rotor of the freeze-dryer and lyophilised overnight .
On the following day lOOμl of culture medium was added to the contents of ten of the vials freeze-dried overnight, while lOOμl of oleic acid (B.P.) was added to the other ten. The groups were labelled "M" and "0" respectively. lOμl of samples from two "M" labelled tubes were transferred to fresh lml vials, and lml of O.lM bicarbonate solution containing 25mg/ml sodium taurocholate was added and mixed well . Under these conditions the oil was dispersed well to give a clear solution.
4 x 20μl aliquots of sample were transferred from the pre-drying control group stored overnight at +4°C to fresh lml vials. To two of these vials was added lml of medium, while to the other two was added lml of O.lM bicarbonate solution containing 25mg/ml sodium taurocholate. The contents of each of the vials was mixed well .
The suspensions prepared above were used to perform 10- fold dilutions in Vero cell monolayer cultures, in order to measure the viability of the polio virus present, the results were expressed as the highest dilution at which 50% cytopathic effects were observed. Nature of sample Highest dilution at which
50% CPE observed
Non- dried control in medium 10 "4/ 10~5 Non-dried control in taurocholate 10 "3/ 10 ~3
Oil - free lyophilate in medium 10 'VlO0
Oil - free lyophilate in taurocholate lO'V lO" 1
Oil -based lyophilate in taurocholate 10"6/10"6
Example 3
2.5ml of distilled water was added to one aliquot of virus particles prepared as described in example 2, and. this group was labelled "W" . 2.5ml of Solulan C24
(lOOmg/ml) was added to another aliquot and mixed gently. This group was labelled "S" .
200μl of each preparation was dispensed into 10 freeze- drying vials, and the remainder in lOOμl aliquots into other tubes as "pre-drying" controls. The controls were stored overnight at +4°C. The freeze-drying vials were placed in the centrifugal rotor of the freeze-dryer and lyophilised overnight.
On the following day lOOμl of culture medium was added to each vial in group "W" and mixed gently. The vials in group "S" were sealed and heated to 60°C in a hot water bath for 5 seconds to melt the Solulan C2 , which resulted in a claer solution. Upon cooling to room temperature this material solidified. 90μl of medium was added to the vials of the "S" group to make the total volume up to lOOμl. lOμl of sample was then transferred from each of groups "S" and "W" to fresh lml vials and lml of medium was added to each and mixed well . To fresh lml vials was added 4 x 20μl of samples from each of the pre-drying groups and lml of medium was added to each. The contents of each vial were mixed well.
The suspensions prepared as described herein were used to perform 10-fold dilutions in Vero cell cultures, to measure the viability of the polio virus present. The results were expressed as the highest dilution at which 50% cytopathic effects were observed.
Nature of Sample Highest Dilution at which 50% CPE observed
Non-dried control + water 10'VlO"6 Non-dried control + Solulan C24 10"s/10"5
Freeze-dried control + water 10"2/10"2
Freeze-dried control + Solulan C24 10"6/10"8

Claims

CLAIMS :
1. A method of storing micro-organisms such that they retain infectivity, which method includes the steps of : -
(i) bringing the micro-organisms into association with an amphiphile; and
(ii) solubilising, suspending or otherwise dispersing the micro-organisms in a hydrophobic phase.
2. A method as claimed in claim 1 wherein the micro¬ organisms are virus particles.
3. A method as claimed in claim 2 wherein the virus particles are polio virus particles.
4. A method as claimed in any one of claims 1 to 3 wherein the hydrophobic solvent is a long chain fatty acid, a medium chain alcohol, a branched long chain alcohol, a monoglyceride, a diglyceride, a medium chain triglyceride, a long chain triglyceride, a halogenated
(e.g. fluorinated) analogue thereof, or a polyoxyethylene-containing lipid.
5. A method as claimed in claim 4 wherein the hydrophobic solvent is mono-, di- or tri-glyceride.
6. A method as claimed in claim 4 wherein the hydrophobic solvent is oleic acid.
7. A method as claimed in any one of claims 1 to 6 which comprises: (i) associating the micro-organisms with an amphiphile in a liquid medium;
(ii) removing the liquid medium to leave an array of amphiphile molecules with their hydrophilic head groups orientated towards the micro-organisms; and
(iii) providing a hydrophobic solvent around the micro-organisms/amphiphile array.
8. A method as claimed in any one of claims 1 to 7 wherein the amphiphile is a phospholipid, a bile salt, a glycolipid, a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24 , polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
9. A method as claimed in claim 8 wherein the amphiphile is a phospholipid which is phosphatidyl choline (PC) , lysophosphatidyl choline (lyso-PC) , sphingomyelin, hexadecyl phosphocholine or an amphiphile polymer containing phosphoryl choline.
10. A method of storing micro-organisms such that they retain infectivity, which method includes the following steps :
(i) bringing the micro-organisms into association with an amphiphile in an aqueous phase; and
(ii) removing the water.
11. A method as claimed in claim 10 wherein the water is removed by freeze-drying.
12. A method as claimed in claim 10 or claim 11 wherein the mixture of amphiphile and micro-organisms is converted to a condensed form by elevating the temperature of the mixture after removal of the water.
13. A method as claimed in any one of claims 10 to 12 w'herein the micro-organisms are virus particles.
14. A method as claimed in claim 13 wherein the virus particles are polio virus particles.
15. A method as claimed in any one of claims 10 to 14 wherein the amphiphile is a phospholipid, a glycolipid, a polyoxyethylene containing surfactant, a lipophilic sulphate, betaine, a sarcosine containing surfactant, Solulan C24, polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
16. A method as claimed in claim 15 wherein the amphiphile is Solulan C24, polyoxyethylene 40 stearate, one of the Tween series of surfactants, one of the Span series of surfactants or a pegolated castor oil derivative, e.g. Cremaphor EL35.
17. A method as claimed in claim 16 wherein the amphiphile is polyoxyethylene 40 stearate.
18. A method as claimed in claim 16 wherein the amphiphile is Solulan C24.
19. A micro-organism composition obtainable by a method as defined in any one of claims 1 to 18.
20. A micro-organism composition as claimed in claim 19 comprising virus particles.
21. A mico-organism composition as claimed in claim 20 comprising polio virus particles.
22. The use of a composition as claimed in claim 20 or claim 21 for the storage of virus particles.
23. The use of a composition as claimed in any one of claims 19 to 21 to induce an immune response in a subject.
24. The use of a composition as claimed in any one of claims 19 to 21 to prepare an agent capable of inducing an immune response in a subject.
PCT/GB1996/002615 1995-10-25 1996-10-25 Methods of preserving microorganisms WO1997015331A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1019980702966A KR19990067029A (en) 1995-10-25 1996-10-25 How to preserve microorganisms
NZ320446A NZ320446A (en) 1995-10-25 1996-10-25 Preserving microorganisms by mixing them with an amphiphile and a hydrophobic solvent
EP96935088A EP0857069A1 (en) 1995-10-25 1996-10-25 Methods of preserving microorganisms
BR9610932-7A BR9610932A (en) 1995-10-25 1996-10-25 Process for storing microorganisms, microorganism composition and use
JP9516410A JP2000501282A (en) 1995-10-25 1996-10-25 How to store microorganisms
AU73183/96A AU714485B2 (en) 1995-10-25 1996-10-25 Methods of preserving microorganisms
US09/065,734 US6165773A (en) 1995-10-25 1998-04-24 Methods of preserving viruses
NO981865A NO981865L (en) 1995-10-25 1998-04-24 Microorganism Conservation Procedures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9521806.1 1995-10-25
GBGB9521806.1A GB9521806D0 (en) 1995-10-25 1995-10-25 Preservation methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/065,734 Continuation US6165773A (en) 1995-10-25 1998-04-24 Methods of preserving viruses

Publications (1)

Publication Number Publication Date
WO1997015331A1 true WO1997015331A1 (en) 1997-05-01

Family

ID=10782855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002615 WO1997015331A1 (en) 1995-10-25 1996-10-25 Methods of preserving microorganisms

Country Status (12)

Country Link
EP (1) EP0857069A1 (en)
JP (1) JP2000501282A (en)
KR (1) KR19990067029A (en)
CN (1) CN1202829A (en)
AU (1) AU714485B2 (en)
BR (1) BR9610932A (en)
CA (1) CA2235495A1 (en)
GB (1) GB9521806D0 (en)
NO (1) NO981865L (en)
NZ (1) NZ320446A (en)
WO (1) WO1997015331A1 (en)
ZA (1) ZA969015B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645608B2 (en) 2004-08-17 2010-01-12 Pml Microbiologicals, Inc. Microorganism specimen storage, hydrating, transfer and applicator device
US9045728B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
US9101607B2 (en) 2010-03-31 2015-08-11 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
US10029007B2 (en) 2011-10-05 2018-07-24 Stabilitech Biopharma Ltd Stabilisation of polypeptides
US10206960B2 (en) 2010-03-31 2019-02-19 Stabilitech Biopharma Ltd Stabilisation of viral particles
US10716859B2 (en) 2010-03-31 2020-07-21 Stabilitech Biopharma Ltd Excipients for stabilising viral particles, polypeptides or biological material
US10806783B2 (en) 2014-04-11 2020-10-20 Stabilitech Biopharma Ltd Vaccine compositions
US10980871B2 (en) 2017-05-08 2021-04-20 Iosbio Ltd Vaccine compositions
US11530379B2 (en) 2020-07-20 2022-12-20 Stratix Labs Corporation Devices and methods for inoculating a target

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010601A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
WO1995013795A1 (en) * 1993-11-16 1995-05-26 Cortecs Limited Hydrophobic preparations
WO1996017594A1 (en) * 1994-12-09 1996-06-13 Cortecs Limited Sequestration agents
WO1996017593A1 (en) * 1994-12-09 1996-06-13 Cortecs Limited Solubilisation aids for hydrophilic macromolecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010601A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
WO1995013795A1 (en) * 1993-11-16 1995-05-26 Cortecs Limited Hydrophobic preparations
WO1996017594A1 (en) * 1994-12-09 1996-06-13 Cortecs Limited Sequestration agents
WO1996017593A1 (en) * 1994-12-09 1996-06-13 Cortecs Limited Solubilisation aids for hydrophilic macromolecules

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645608B2 (en) 2004-08-17 2010-01-12 Pml Microbiologicals, Inc. Microorganism specimen storage, hydrating, transfer and applicator device
US9101607B2 (en) 2010-03-31 2015-08-11 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
US10206960B2 (en) 2010-03-31 2019-02-19 Stabilitech Biopharma Ltd Stabilisation of viral particles
US10716859B2 (en) 2010-03-31 2020-07-21 Stabilitech Biopharma Ltd Excipients for stabilising viral particles, polypeptides or biological material
US9045728B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
US9610309B2 (en) 2010-12-02 2017-04-04 Oncolytics Biotech Inc. Liquid viral formulations
US9610352B2 (en) 2010-12-02 2017-04-04 Oncolytics Biotech Inc. Lyophilized viral formulations
US10029007B2 (en) 2011-10-05 2018-07-24 Stabilitech Biopharma Ltd Stabilisation of polypeptides
US10806783B2 (en) 2014-04-11 2020-10-20 Stabilitech Biopharma Ltd Vaccine compositions
US10980871B2 (en) 2017-05-08 2021-04-20 Iosbio Ltd Vaccine compositions
US11530379B2 (en) 2020-07-20 2022-12-20 Stratix Labs Corporation Devices and methods for inoculating a target

Also Published As

Publication number Publication date
CN1202829A (en) 1998-12-23
NO981865D0 (en) 1998-04-24
ZA969015B (en) 1998-04-28
AU714485B2 (en) 2000-01-06
NZ320446A (en) 1999-05-28
CA2235495A1 (en) 1997-05-01
EP0857069A1 (en) 1998-08-12
BR9610932A (en) 1999-12-21
GB9521806D0 (en) 1996-01-03
AU7318396A (en) 1997-05-15
KR19990067029A (en) 1999-08-16
NO981865L (en) 1998-06-24
JP2000501282A (en) 2000-02-08

Similar Documents

Publication Publication Date Title
KR100357804B1 (en) Particulate matter-containing glass polysomes, preparation methods thereof and liposome preparations containing them
US5089181A (en) Method of dehydrating vesicle preparations for long term storage
FI63856C (en) FOER FARING FRAMSTAELLNING AV LIPOSOM-PRECURSORER
Gregory et al. Wetting agents for biological electron microscopy: I. General considerations and negative staining
AU714485B2 (en) Methods of preserving microorganisms
CN114557971B (en) Freeze-drying protective agent for nucleic acid-lipid nano particles, and preparation method and application thereof
Shands The physical structure of bacterial lipopolysaccharides
US6165773A (en) Methods of preserving viruses
AU704292B2 (en) Solubilisation methods
Rosenthal et al. Disruption of Escherichia coli outer membranes by EM 49. A new membrane active peptide antibiotic
Könnings et al. A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method
JP2677647B2 (en) Dehydration method for lipomeric preparations
FR2545837A1 (en) TRANSFORMATION OF LIPOSOME-PROMOTED EUKARYOTIC CELLS
Nounou et al. Influence of different sugar cryoprotectants on the stability and physico-chemical characteristics of freeze-dried 5-fluorouracil plurilamellar vesicles
MXPA98003198A (en) Methods to preserve microorganis
HANDA et al. Lyophilized liposomes prepared by a modified reversed-phase evaporation method
KR101687735B1 (en) Method for production of liposome powder with novel freeze drying supplement and novel solvent for phosphlipid
CN115444797B (en) Preparation method of Hibiscus sabdariffa liposome freeze-dried powder, hibiscus sabdariffa liposome freeze-dried powder and application of Hibiscus sabdariffa liposome freeze-dried powder
CA2173601C (en) Liposomes containing particulate materials
Nermut et al. Negative staining of freeze‐fractured envelopes of Escherichia coli K12
JPH013115A (en) liposome formulation
RU98109895A (en) METHODS OF STORAGE OF MICROORGANISMS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96198528.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2235495

Country of ref document: CA

Ref document number: 2235495

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/003198

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1997 516410

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980702966

Country of ref document: KR

Ref document number: 09065734

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 320446

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1996935088

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996935088

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019980702966

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019980702966

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996935088

Country of ref document: EP